Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway

Multidrug resistance (MDR) is one of the major obstacles to the efficiency of cancer chemotherapy, which often results from the overexpression of drug efflux transporters such as P-glycoprotein (P-gp). In the present study, we determined the effect of dasatinib which was approved for imatinib resist...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Biol Ther
Main Authors: Chen, Ting, Wang, Changyuan, Liu, Qi, Meng, Qiang, Sun, Huijun, Huo, Xiaokui, Sun, Pengyuan, Peng, Jinyong, Liu, Zhihao, Yang, Xiaobo, Liu, Kexin
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2014
Assuntos:
Research Papers
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622436/
https://ncbi.nlm.nih.gov/pubmed/25482933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/15384047.2014.987062
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares